Journal
NATURE BIOTECHNOLOGY
Volume 40, Issue 3, Pages 291-295Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41587-022-01246-w
Keywords
-
Categories
Ask authors/readers for more resources
Protective encapsulating devices and gene-editing technologies may eliminate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available